It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Invasive extravillous cytotrophoblast of the human placenta expresses galectins-1, -3, and -8 in vivo and in vitro. This study aimed to investigate the potential role of galectin-3 in cell migration and invasion, using recombinant human galectin-3 (rhgalectin-3), small molecule galectin inhibitor I47, and galectin-3 silencing. HTR-8/SVneo cell migration was stimulated by rhgalectin-3 and reduced by I47, which could be neutralised by rhgalectin-3. Inhibitor specificity and selectivity for the galectins expressed in extravillous trophoblast were validated in solid phase assays using recombinant galectin-1, -3, -8, confirming selectivity for galectin-3. HTR-8/SVneo cell migration and invasion, and invasion by isolated trophoblast cells in primary culture were significantly reduced in the presence of I47, which could be restored by rhgalectin-3. Upon HTR-8/SVneo cell treatment with galectin-3 siRNA both LGALS3 and galectin-3 protein were dramatically decreased. Silencing of galectin-3 induced significant reduction in cell migration and invasion, which was restored by rhgalectin-3. The influence on known mediators of cell invasion, MMP2 and -9, and integrins α1, α5, and β1 was followed in silenced cells, showing lower levels of MMPs and a large reduction in integrin subunit β1. These results show that galectin-3 acts as a pro-invasive autocrine/paracrine factor in trophoblast in vitro.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University of Belgrade, Banatska 31b, Laboratory for Biology of Reproduction, Institute for the Application of Nuclear Energy, Belgrade, Serbia (GRID:grid.7149.b) (ISNI:0000 0001 2166 9385)
2 University of Belgrade, Banatska 31b, Laboratory for Biology of Reproduction, Institute for the Application of Nuclear Energy, Belgrade, Serbia (GRID:grid.7149.b) (ISNI:0000 0001 2166 9385); Guy’s Hospital, London SE1 9RT, King’s College London, Faculty of Life Sciences & Medicine, Department of Women & Children’s Health, London, United Kingdom (GRID:grid.239826.4)
3 Medicinaregatan 8A, Galecto Biotech AB, Sahlgrenska Science Park, Gothenburg, Sweden (GRID:grid.7149.b)
4 Lund University, POB 124, Centre for Analysis and Synthesis, Department of Chemistry, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
5 BMC-C1228b, Klinikgatan 28, Section MIG, Department of Laboratory Medicine Lund University, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)